{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "c1b11442",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Core imports for scientific poster analysis\n",
    "from mcp import stdio_client, StdioServerParameters  # Model Context Protocol for tool integration\n",
    "from strands import Agent                            # Strands Agent SDK for orchestrating AI workflows\n",
    "from strands.tools.mcp import MCPClient             # MCP client wrapper for Strands\n",
    "from strands.models import BedrockModel             # Amazon Bedrock model integration\n",
    "from strands_tools import file_read, file_write, shell  # Built-in Strands tools\n",
    "import os\n",
    "import urllib3"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "143f2b7c",
   "metadata": {},
   "source": [
    "# Scientific Poster Data Extraction with AI\n",
    "\n",
    "## Overview\n",
    "\n",
    "This notebook demonstrates how to extract structured insights from scientific posters using cutting-edge AI technologies. We combine the power of **Amazon Bedrock Data Automation** with the **Strands Agent SDK** to create an intelligent document processing pipeline.\n",
    "\n",
    "## Value Proposition\n",
    "\n",
    "### Why Amazon Bedrock Data Automation MCP?\n",
    "\n",
    "[Amazon Bedrock Data Automation](https://aws.amazon.com/bedrock/bda/) provides enterprise-grade capabilities for processing unstructured multimodal content:\n",
    "\n",
    "- **Multimodal Understanding**: Processes documents, images, audio, and video with state-of-the-art AI models\n",
    "- **Scalable Infrastructure**: Handles large volumes of content with AWS's robust cloud infrastructure\n",
    "- **Pre-built Intelligence**: Leverages foundation models trained on diverse scientific and technical content\n",
    "- **Cost-Effective**: Pay-per-use model eliminates the need for maintaining specialized ML infrastructure\n",
    "- **Security & Compliance**: Enterprise-grade security with data residency and privacy controls\n",
    "\n",
    "### Why Strands Agent SDK?\n",
    "\n",
    "The [Strands Agent SDK](https://strandsagents.com/0.1.x/) provides a powerful framework for building AI agents:\n",
    "\n",
    "- **Tool Integration**: Seamlessly connects with external services via Model Context Protocol (MCP)\n",
    "- **Workflow Orchestration**: Manages complex multi-step AI workflows with error handling and retries\n",
    "- **Model Flexibility**: Works with various LLMs including Amazon Bedrock models\n",
    "- **Developer Experience**: Intuitive Python API that reduces boilerplate code\n",
    "- **Production Ready**: Built-in logging, monitoring, and debugging capabilities\n",
    "\n",
    "### Combined Benefits\n",
    "\n",
    "Together, these technologies enable:\n",
    "- **Rapid Prototyping**: From concept to working solution in minutes\n",
    "- **Scientific Accuracy**: Specialized understanding of research content and terminology\n",
    "- **Structured Output**: Convert unstructured posters into queryable, structured data\n",
    "- **Scalable Processing**: Handle individual files or batch process hundreds of documents\n",
    "\n",
    "## Use Cases\n",
    "\n",
    "This approach is particularly valuable for:\n",
    "- **Research Institutions**: Digitizing and cataloging poster sessions from conferences\n",
    "- **Pharmaceutical Companies**: Analyzing clinical trial posters and research findings\n",
    "- **Academic Libraries**: Creating searchable databases of research presentations\n",
    "- **Grant Agencies**: Reviewing and categorizing funded research outcomes\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "420313c8",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Configuration: Disable SSL warnings for development\n",
    "# Note: Remove this in production environments for security\n",
    "urllib3.disable_warnings(urllib3.exceptions.InsecureRequestWarning)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ddb78113",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Configuration: Input file and AWS settings\n",
    "pdf_path = os.path.abspath(\"/Users/necibea/poster.pdf\")  # Path to scientific poster PDF\n",
    "\n",
    "# Initialize Amazon Bedrock Data Automation MCP Client\n",
    "# This client provides access to BDA's multimodal processing capabilities\n",
    "# through the Model Context Protocol (MCP) interface\n",
    "aws_bda_client = MCPClient(\n",
    "    lambda: stdio_client(\n",
    "        StdioServerParameters(\n",
    "            command=\"uvx\",  # Use uvx to run the MCP server\n",
    "            args=[\"awslabs.aws-bedrock-data-automation-mcp-server@latest\"],\n",
    "            env={\n",
    "                \"AWS_PROFILE\": \"default\",                    # AWS credentials profile\n",
    "                \"AWS_REGION\": \"us-east-1\",                     # AWS region for BDA service\n",
    "                \"AWS_BUCKET_NAME\": \"clinical-poster-analysis-bucket\",  # S3 bucket for temporary storage\n",
    "                \"BASE_DIR\": \"/Users/necibea/\",                # Base directory for file operations\n",
    "                \"FASTMCP_LOG_LEVEL\": \"ERROR\"                 # Reduce log verbosity\n",
    "            }\n",
    "        )\n",
    "    )\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "analysis_process",
   "metadata": {},
   "source": [
    "## Analysis Process\n",
    "\n",
    "The following cell demonstrates the core functionality of our poster analysis pipeline:\n",
    "\n",
    "1. **Document Upload**: The PDF is automatically uploaded to the configured S3 bucket\n",
    "2. **Multimodal Processing**: BDA analyzes both text and visual elements (figures, tables, charts)\n",
    "3. **Structure Extraction**: The service identifies document hierarchy, sections, and relationships\n",
    "4. **Content Analysis**: Advanced AI models extract semantic meaning from scientific content\n",
    "5. **Structured Output**: Results are returned in JSON format with rich metadata\n",
    "\n",
    "### Key Features Demonstrated\n",
    "\n",
    "- **Element Detection**: Automatically identifies figures, tables, and text blocks\n",
    "- **Markdown Conversion**: Converts poster content to structured markdown format\n",
    "- **Metadata Extraction**: Provides detailed statistics about document composition\n",
    "- **Visual Understanding**: Processes charts, graphs, and scientific diagrams\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d72f610f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"invocationArn\": \"arn:aws:bedrock:us-east-1:774305571746:data-automation-invocation/8b41086a-144d-4a6c-8583-cb6745d42b88\",\n",
      "  \"standardOutput\": {\n",
      "    \"metadata\": {\n",
      "      \"asset_id\": \"0\",\n",
      "      \"logical_subdocument_id\": \"0\",\n",
      "      \"semantic_modality\": \"DOCUMENT\",\n",
      "      \"s3_bucket\": \"clinical-poster-analysis-bucket\",\n",
      "      \"s3_key\": \"mcp/3da7fe2a-60d0-4104-ac8b-464e37c1647d.pdf\",\n",
      "      \"number_of_pages\": 1,\n",
      "      \"start_page_index\": 0,\n",
      "      \"end_page_index\": 0,\n",
      "      \"file_type\": \"PDF\"\n",
      "    },\n",
      "    \"document\": {\n",
      "      \"statistics\": {\n",
      "        \"element_count\": 52,\n",
      "        \"table_count\": 1,\n",
      "        \"figure_count\": 20,\n",
      "        \"hyperlink_count\": 0\n",
      "      }\n",
      "    },\n",
      "    \"pages\": [\n",
      "      {\n",
      "        \"id\": \"bfe3462e-de3c-43b4-aba5-8fdd58d5a780\",\n",
      "        \"page_index\": 0,\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"# Isolation of Tumor-Infiltrating Leukocytes from Mouse Tumors\\n\\n# Grace F.T. Poon1, Lyz Boyd¹, Siobhan Ennis1, Joe Deng¹, Andy I. Kokaji1, Allen C. Eaves¹,², Sharon A. Louis1, and Frann Antignano¹\\n\\nSTEMCELL Technologies Inc., Vancouver BC, Canada; ²Terry Fox Laboratory, BC Cancer Agency, Vancouver BC, Canada\\n\\n## INTRODUCTION\\n\\nCell-based immunotherapy is being evaluated in various types of cancer and it is one of the most rapidly growing and promising areas of cancer research. Tumor-infiltrating leukocytes (TILs) consist of highly diverse leukocyte subsets with major roles in cancer immune surveillance. Due to their relatively low frequency, tumor heterogeneity, and the abundance of tissue debris in tumor samples, it is difficult to isolate or analyze TILs with sensitivity and precision. To address this challenge, we have developed a simple method for isolating CD45+ TILs from mouse tumors. Performance was evaluated in three commonly used mouse models, namely the B16-F10 (B16) melanoma, CT26.WT (CT26) colon carcinoma, and 4T1 mammary tumor models. Solid tumors were induced by subcutaneous implantation of B16, CT26, and 4T1 cancer cell lines into syngeneic recipients. The protocol can be easily modified to achieve higher purity or recovery as required, and accomodates a wide range of sample sizes. Importantly, major immune subsets including T cells, B cells, and myeloid cells are recovered after isolation. EasySepᵀ Mouse TIL (CD45) Positive Selection Kit allows researchers to isolate leukocytes from tumors with ease, improving the TIL downstream workflow. Furthering our understanding of TILs will be essential for developing effective immunotherapeutic strategies.\\n\\n## METHODS\\n\\n\\\\*Mix Component A, B, and C at a 1:1:6 ratio\\n\\nFIGURE 1. EasySep TM Mouse TIL (CD45) Positive Selection Protocol\\n\\n| Prepare EasySepᵀ TIL (CD45) Positive Selection Cocktail\\\\*   | Add EasySepᵀ TIL (CD45) Positive Selection Cocktail   | Add EasySepᵀ Dextran RapidSpheres™   | Repeat for Total of 4 x 5-Minute Separations Top up with EasySep™ Buffer   | Repeat for Total of 4 x 5-Minute Separations Place Tube in Magnet   | Repeat for Total of 4 x 5-Minute Separations Discard Pour-off   | Collect CD45+ TILs from EasySep™ Magnet   |\\n|-------------------------------------------------------------|-------------------------------------------------------|--------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------|\\n|                                                             | Incubate 5 minutes                                    | for Incubate for 3 minutes           |                                                                            | +EasySep Incubate 5                                                 | for minutes                                                     |                                           |\\n\\n## RESULTS\\n\\n![CHART](./0b63777c-976d-4812-b3f9-a4f0eba2d5e1.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\n\\n![CHART](./1e346caf-8142-40c9-89d7-76c70eef2bb6.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\n\\n![CHART](./76f26779-a5f3-4971-bb5e-fff291727432.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\n\\n![CHART](./463f2e6e-3171-4b6d-9bd3-0be4597b7ec3.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\n\\n![CHART](./99f65e0b-38df-4475-90ae-1f12e447ab22.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\n\\n![CHART](./3cd5bd63-7c76-4789-a1b2-9cedc4cab5a0.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\n\\n![CHART](./7d6a9dae-b105-4c07-839c-0227f3f75916.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\n\\n![CHART](./33970edf-f1fe-4fe4-83fa-39ef915f1379.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\n\\n![CHART](./789109db-aa29-4e9a-a567-e1d02ed7f210.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\n\\n![CHART](./b512e9ee-b145-4fc9-bab7-6cd5c7a63431.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\n\\n![CHART](./2f446d7c-f43a-4b2e-908f-8df0b1b6ad23.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\n\\n![CHART](./eba4eab7-5e48-4f43-bfc2-6204d1d39e1d.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\n\\n330\\n\\n18\\n\\nFSC 10000)\\n\\n240\\n\\n![CHART](./3078f5a8-0a93-4493-b20b-ea52d37b47c0.png)\\n\\n100\\n83.2\\n TILs\\n\\n73.3\\n\\n75\\n\\n36.1\\n\\n30.4\\n\\n50\\n25.4\\n Viable\\n\\n25\\n\\n0\\n\\nStart\\nIsolated\\nStart\\nIsolated\\nStart\\nIsolated\\n B16\\nCT26\\n4T1\\n\\nFIGURE 3. Performance of EasySep™ Mouse TIL (CD45) Positive Selection Kit in Three Tumor models. TIL isolation from B16, CT26, and 4T1 samples starting at 1 - 10 X 10⁷ cells/mL, using the EasySepᵀ (purple) Magnet. Data shown as mean purity +/- SD.\\n92.8\\n90.9\\n\\n100\\n78.3\\n76.6\\n84.7\\n TILs\\n\\n80\\n\\n60\\n\\n22.4\\n\\nViable\\n40\\n\\n20\\n\\n0\\n\\nStart\\nPurple\\nEE 5mL\\nSilver\\n14mL\\n\\nFIGURE 4. Compatibility of CD45 Positive Selection Protocol with Various EasySep™ Magnets. TIL isolation from B16 tumor samples using the EasySepᵀ (purple), Big EasyᵀM (silver), and EasyEights™ (EE) Magnets. Samples are prepared at 1 2.5 X 10⁷ cells/mL, 0.5 1 mL. Data shown as mean purity +/- SD. Each color represents an independent experiment.\\n\\nMagnet Type\\n\\nFIGURE 3. Performance of EasySep™ Mouse TIL (CD45) Positive Selection Kit in Three Tumor models. TIL isolation from B16, CT26, and 4T1 samples starting at 1 - 10 X 10⁷ cells/mL, using the EasySepᵀ (purple) Magnet. Data shown as mean purity +/- SD.\\nFIGURE 4. Compatibility of CD45 Positive Selection Protocol with Various EasySep™ Magnets. TIL isolation from B16 tumor samples using the EasySepᵀ (purple), Big EasyᵀM (silver), and EasyEights™ (EE) Magnets. Samples are prepared at 1 2.5 X 10⁷ cells/mL, 0.5 1 mL. Data shown as mean purity +/- SD. Each color represents an independent experiment.\\n\\n![CHART](./09795b74-0211-4589-8695-52cbfb567579.png)\\n\\n100\\n83.2\\n TILs\\n\\n73.3\\n\\n75\\n\\n36.1\\n\\n30.4\\n\\n50\\n25.4\\n Viable\\n\\n25\\n\\n0\\n\\nStart\\nIsolated\\nStart\\nIsolated\\nStart\\nIsolated\\n B16\\nCT26\\n4T1\\n\\nFIGURE 3. Performance of EasySep™ Mouse TIL (CD45) Positive Selection Kit in Three Tumor models. TIL isolation from B16, CT26, and 4T1 samples starting at 1 - 10 X 10⁷ cells/mL, using the EasySepᵀ (purple) Magnet. Data shown as mean purity +/- SD.\\n92.8\\n90.9\\n\\n100\\n78.3\\n76.6\\n84.7\\n TILs\\n\\n80\\n\\n60\\n\\n22.4\\n\\nViable\\n40\\n\\n20\\n\\n0\\n\\nStart\\nPurple\\nEE 5mL\\nSilver\\n14mL\\n\\nFIGURE 4. Compatibility of CD45 Positive Selection Protocol with Various EasySep™ Magnets. TIL isolation from B16 tumor samples using the EasySepᵀ (purple), Big EasyᵀM (silver), and EasyEights™ (EE) Magnets. Samples are prepared at 1 2.5 X 10⁷ cells/mL, 0.5 1 mL. Data shown as mean purity +/- SD. Each color represents an independent experiment.\\n\\nMagnet Type\\n\\nFIGURE 3. Performance of EasySep™ Mouse TIL (CD45) Positive Selection Kit in Three Tumor models. TIL isolation from B16, CT26, and 4T1 samples starting at 1 - 10 X 10⁷ cells/mL, using the EasySepᵀ (purple) Magnet. Data shown as mean purity +/- SD.\\nFIGURE 4. Compatibility of CD45 Positive Selection Protocol with Various EasySep™ Magnets. TIL isolation from B16 tumor samples using the EasySepᵀ (purple), Big EasyᵀM (silver), and EasyEights™ (EE) Magnets. Samples are prepared at 1 2.5 X 10⁷ cells/mL, 0.5 1 mL. Data shown as mean purity +/- SD. Each color represents an independent experiment.\\n\\n![CHART](./c39881fd-1c8f-4411-9639-f7d191fc2d6f.png)\\n\\nA\\n96.1\\n95.6\\n\\n100\\n91.6\\n85.7\\n TILs\\n\\n80\\n\\n60\\n30.4\\n\\nViable\\n\\n40\\n\\n20\\n\\n0\\n\\nStart\\n10\\n5\\n2.5\\n1\\n Start Cell Concentration (x 10⁷ cells/mL)\\nB\\n\\n![CHART](./b09ee52d-b2f0-4a64-adf6-3344083f6ce9.png)\\n\\nViable TIL Recovery\\n100\\n\\n53.9\\n\\n53.6\\n\\n80-\\n\\n36.6\\n\\n60\\n\\n22.0\\n\\n40\\n\\n20\\n\\n0\\n\\n10\\n5\\n2.5\\n Start Cell Concentration (x 10⁷cells/mL)\\n\\n![CHART](./e814226d-13f6-4d5e-9c1e-20eebaf813ff.png)\\n\\nViable CD457 TIL Recovery\\n100\\n\\n57.0\\n\\n80\\n\\n50.6\\n\\n39.9\\n49.4\\n\\n60\\n38.9\\n37.3\\n\\n40\\n\\n20\\n\\n0\\n\\n0.1\\n0.25\\n0.5\\n1\\n1.5\\n2\\n Start Volume (mL)\\n\\nNo Gate\\nGated on Singlets\\n\\nB16 Start\\n\\n![CHART](./1f683841-d932-4796-a96e-5846c0cc986f.png)\\n\\nc\\n100\\n87.8\\n85.5\\n81.2\\n72.5\\n72.3\\n75.6\\n Viable TILs\\n80\\n\\n60\\n34.9\\n\\n40\\n\\n20\\n\\n0\\n\\nStart\\n0.1\\n0.25\\n0.5\\n1\\n1.5\\n2\\n Start Volume (mL)\\nD\\nFIGURE 5. Higher TIL Purity or Recovery can be Achieved by Adjusting the Start Concentration and Volume. CD45+ TIL purity and recovery in B16 samples at various start cell concentrations (A,B), and across different start volumes at 1 X 10⁷ cells/mL (C,D) using the EasySepᵀ (purple) Magnet. Data shown as mean purity or recovery +/- SD. Each color represents an independent experiment.\\n\\n![CHART](./2a4fc1a0-fbac-476b-a502-8ee64493d1a0.png)\\n\\nCD45+ CD45.2+\\n 23.1\\n\\nFITC\\n\\n10\\n\\n10\\n\\n104\\n105\\n\\nFSC\\n\\nB16 Isolated\\n\\nFSC\\n\\n![CHART](./05a82d6d-c847-42ad-910c-2e66a480b62e.png)\\n\\n3.6x10&quot;\\n\\nSize\\n 73.1\\n\\n2.4 x10\\n\\nSSC\\n\\n1.1x10\\n\\n9.5x10*\\n\\n38x10\\n96x10\\n19x10&quot;\\n28x10&quot;\\n37x1\\n\\n![CHART](./8efc99a9-2767-417d-9b4f-4d6dcb8b337e.png)\\n\\nGated on PI- Viable Cells\\n\\n10,\\n\\nPI\\n\\n53.7\\n\\n10⁴\\n\\n21x10\\n\\nFSC\\n\\n![CHART](./e963f076-5597-49c7-bafc-3b8aee34bbea.png)\\n\\nCD4+\\n 24.5\\n\\n10&quot;\\n\\n10&quot;\\nCD8+\\n\\n41.6\\n\\n10³\\n104\\n105\\n CD8 BV785\\n\\nFIGURE 6. Immune Cell Composition of a B16 Tumor Before and After EasySep™ TIL (CD45) Positive Selection.\\n\\n![CHART](./8f85b186-f746-4e99-85b5-7338b6ee0550.png)\\n\\nCD45 BV421\\n\\n3.6x10\\n\\n75.0\\n\\n2.4 x10\\n\\nSSC\\n\\n1.1x10\\n\\n-9.5x10*\\n\\n38x10\\nAAXIN\\n19x1n\\n28x10\\n37x1\\n\\n![CHART](./9cb42f03-9893-419d-ac93-c90e0efd5465.png)\\n\\nCD4\\n\\nPI\\n\\n46.5\\n\\n2x103\\nRdx10\\n28 x1\\n\\n![CHART](./8c613efb-2f16-4a08-b760-a49024db67d8.png)\\n\\nGated on\\n CD45+ TILs\\n\\n10\\n\\nCD19+ CD3-\\n 23.0\\n\\n10⁵\\n\\nCD3+ CD19\\n\\n60.9\\n15.2\\n\\n10&quot;\\n10&quot;\\n10°\\n\\nCD3 APC\\n\\nFSC\\n\\n![CHART](./15b7005f-6f96-4ee7-acd4-59f849ba5714.png)\\n\\nGated on CD3+ CD19\\n\\nGr1 BV605\\n\\nCD45+ CD45.2+\\n 97.2\\n\\nCD45. FITC\\n\\n104\\n\\nOUO\\n\\n104\\n10\\n10&quot;\\n CD45 BV421\\n\\n![CHART](./357399e6-f151-4111-872e-7e18ca91a583.png)\\n\\nCD4+\\n 43.1\\n\\n10\\n\\n10&quot;\\n\\nCD8+\\n 31.1\\n\\n10\\n\\nCD8 BV785\\n\\n![CHART](./a1a37ce8-1c3d-4f55-8070-0ecdef049d8a.png)\\n\\nGated on CD3 CD19\\n\\n10°\\nCD11b+\\n\\n46.2\\n\\n10\\n\\n104\\n10\\n\\nCD11b Alexa700\\n\\n![CHART](./ab736b76-a3b8-47b4-9df1-0fafd07f250a.png)\\n\\nCD19+ CD3-\\n 9.6\\n\\n10\\n\\nCD3-\\nCD19\\n\\n29.3\\n\\n103\\n104\\n105\\n10°\\n CD3 APC\\n\\nCD4 PE-Cy7\\n\\n![CHART](./9f7e6f03-530d-4fa2-9ab4-6719504598dc.png)\\n\\nGr1 BV605\\n10\\nGr1+ 1b+\\n\\n103\\n10°\\n10°\\n\\nCD1 Alexa700\\n\\n## Summary\\n\\n- EasySep™ Mouse TIL (CD45) Positive Selection Kit enables the isolation of leukocytes from solid tumors in as little as 30 minutes, while achieving purity as high as 98%.\\n- The isolation protocol can accommodate different sample volumes and cell densities due to tumor tissue heterogeneity.\\n- TIL purity or recovery can be optimized by adjusting the starting cell concentration or volume.\\n- TIL immune cell composition of the starting sample is maintained following EasySep™ isolation.\\n\\n![LOGO](./e2995683-e1f8-45bc-be53-923be1f0fc8b.png)\\n\\nSTEMCELL\\nTM\\n\\nTECHNOLOGIES\\n\\nTOLL-FREE PHONE 1 800 667\\n\\nPHONE 1 604 877 0713\\n\\nINFO@STEMCELL.COM\\n\\nTECHSUPPORT@STEMCELL.COM\\n\\nFOR RESEARCH USE ONLY. NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES STEMCELL TECHNOLOGIES INC.'S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485 MEDICAL DEVICE STANDARDS.\\n\\n**FOR GLOBAL CONTACT DETAILS VISIT WWW.STEMCELL.COM**\"\n",
      "        },\n",
      "        \"statistics\": {\n",
      "          \"element_count\": 52,\n",
      "          \"table_count\": 1,\n",
      "          \"figure_count\": 20,\n",
      "          \"hyperlink_count\": 0\n",
      "        },\n",
      "        \"asset_metadata\": {\n",
      "          \"rectified_image_width_pixels\": 6234,\n",
      "          \"rectified_image_height_pixels\": 6234,\n",
      "          \"corners\": [\n",
      "            [\n",
      "              -1.004705236036119e-6,\n",
      "              -6.009609147758104e-6\n",
      "            ],\n",
      "            [\n",
      "              1.0000001566510266,\n",
      "              -9.861920252418458e-8\n",
      "            ],\n",
      "            [\n",
      "              1.0000006266041066,\n",
      "              1.0000011748826998\n",
      "            ],\n",
      "            [\n",
      "              4.064207998925164e-8,\n",
      "              1.0000001566510266\n",
      "            ]\n",
      "          ]\n",
      "        }\n",
      "      }\n",
      "    ],\n",
      "    \"elements\": [\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"53c3353a-ed22-4bae-bc46-de9e0f1edd2b\",\n",
      "        \"reading_order\": 0,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"# Isolation of Tumor-Infiltrating Leukocytes from Mouse Tumors\"\n",
      "        },\n",
      "        \"sub_type\": \"TITLE\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"bd066b04-1e9e-4ee7-bc56-eb710230aa63\",\n",
      "        \"reading_order\": 1,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"# Grace F.T. Poon1, Lyz Boyd¹, Siobhan Ennis1, Joe Deng¹, Andy I. Kokaji1, Allen C. Eaves¹,², Sharon A. Louis1, and Frann Antignano¹\"\n",
      "        },\n",
      "        \"sub_type\": \"HEADER\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"a88d89c0-8d1a-4025-b145-fb5773221efc\",\n",
      "        \"reading_order\": 2,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"STEMCELL Technologies Inc., Vancouver BC, Canada; ²Terry Fox Laboratory, BC Cancer Agency, Vancouver BC, Canada\"\n",
      "        },\n",
      "        \"sub_type\": \"PARAGRAPH\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"0496a40e-aeb5-4825-8c2a-60b142fe326f\",\n",
      "        \"reading_order\": 3,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"## INTRODUCTION\"\n",
      "        },\n",
      "        \"sub_type\": \"SECTION_HEADER\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"80b2953e-2e8b-4369-82b4-ec18c6af3e07\",\n",
      "        \"reading_order\": 4,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"Cell-based immunotherapy is being evaluated in various types of cancer and it is one of the most rapidly growing and promising areas of cancer research. Tumor-infiltrating leukocytes (TILs) consist of highly diverse leukocyte subsets with major roles in cancer immune surveillance. Due to their relatively low frequency, tumor heterogeneity, and the abundance of tissue debris in tumor samples, it is difficult to isolate or analyze TILs with sensitivity and precision. To address this challenge, we have developed a simple method for isolating CD45+ TILs from mouse tumors. Performance was evaluated in three commonly used mouse models, namely the B16-F10 (B16) melanoma, CT26.WT (CT26) colon carcinoma, and 4T1 mammary tumor models. Solid tumors were induced by subcutaneous implantation of B16, CT26, and 4T1 cancer cell lines into syngeneic recipients. The protocol can be easily modified to achieve higher purity or recovery as required, and accomodates a wide range of sample sizes. Importantly, major immune subsets including T cells, B cells, and myeloid cells are recovered after isolation. EasySepᵀ Mouse TIL (CD45) Positive Selection Kit allows researchers to isolate leukocytes from tumors with ease, improving the TIL downstream workflow. Furthering our understanding of TILs will be essential for developing effective immunotherapeutic strategies.\"\n",
      "        },\n",
      "        \"sub_type\": \"PARAGRAPH\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"2769e2fa-dd03-4453-9fc0-f9b3cba76206\",\n",
      "        \"reading_order\": 5,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"## METHODS\"\n",
      "        },\n",
      "        \"sub_type\": \"SECTION_HEADER\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"dbc01d8b-911d-4a31-b4a1-6bae0961f931\",\n",
      "        \"reading_order\": 6,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"\\\\*Mix Component A, B, and C at a 1:1:6 ratio\\n\\nFIGURE 1. EasySep TM Mouse TIL (CD45) Positive Selection Protocol\"\n",
      "        },\n",
      "        \"sub_type\": \"PARAGRAPH\"\n",
      "      },\n",
      "      {\n",
      "        \"id\": \"a678b885-5a6a-4482-a996-abd9ab6db0ab\",\n",
      "        \"reading_order\": 7,\n",
      "        \"type\": \"TABLE\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"| Prepare EasySepᵀ TIL (CD45) Positive Selection Cocktail\\\\*   | Add EasySepᵀ TIL (CD45) Positive Selection Cocktail   | Add EasySepᵀ Dextran RapidSpheres™   | Repeat for Total of 4 x 5-Minute Separations Top up with EasySep™ Buffer   | Repeat for Total of 4 x 5-Minute Separations Place Tube in Magnet   | Repeat for Total of 4 x 5-Minute Separations Discard Pour-off   | Collect CD45+ TILs from EasySep™ Magnet   |\\n|-------------------------------------------------------------|-------------------------------------------------------|--------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------|\\n|                                                             | Incubate 5 minutes                                    | for Incubate for 3 minutes           |                                                                            | +EasySep Incubate 5                                                 | for minutes                                                     |                                           |\"\n",
      "        },\n",
      "        \"title\": \"\",\n",
      "        \"footers\": [],\n",
      "        \"headers\": [\n",
      "          \"Prepare EasySepᵀ TIL (CD45) Positive Selection Cocktail*\",\n",
      "          \"Add EasySepᵀ TIL (CD45) Positive Selection Cocktail\",\n",
      "          \"Add EasySepᵀ Dextran RapidSpheres™\",\n",
      "          \"Repeat for Total of 4 x 5-Minute Separations Top up with EasySep™ Buffer\",\n",
      "          \"Repeat for Total of 4 x 5-Minute Separations Place Tube in Magnet\",\n",
      "          \"Repeat for Total of 4 x 5-Minute Separations Discard Pour-off\",\n",
      "          \"Collect CD45+ TILs from EasySep™ Magnet\"\n",
      "        ]\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"ebfd01a0-7e48-4760-90d0-fe72c199c02a\",\n",
      "        \"reading_order\": 8,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"## RESULTS\"\n",
      "        },\n",
      "        \"sub_type\": \"SECTION_HEADER\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"0b63777c-976d-4812-b3f9-a4f0eba2d5e1\",\n",
      "        \"reading_order\": 9,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"Start\\nB16\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./0b63777c-976d-4812-b3f9-a4f0eba2d5e1.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"1e346caf-8142-40c9-89d7-76c70eef2bb6\",\n",
      "        \"reading_order\": 10,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"Start\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./1e346caf-8142-40c9-89d7-76c70eef2bb6.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"76f26779-a5f3-4971-bb5e-fff291727432\",\n",
      "        \"reading_order\": 11,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"Isolated\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./76f26779-a5f3-4971-bb5e-fff291727432.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"463f2e6e-3171-4b6d-9bd3-0be4597b7ec3\",\n",
      "        \"reading_order\": 12,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"Isolated\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./463f2e6e-3171-4b6d-9bd3-0be4597b7ec3.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"99f65e0b-38df-4475-90ae-1f12e447ab22\",\n",
      "        \"reading_order\": 13,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"4T1\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./99f65e0b-38df-4475-90ae-1f12e447ab22.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"3cd5bd63-7c76-4789-a1b2-9cedc4cab5a0\",\n",
      "        \"reading_order\": 14,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./3cd5bd63-7c76-4789-a1b2-9cedc4cab5a0.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"7d6a9dae-b105-4c07-839c-0227f3f75916\",\n",
      "        \"reading_order\": 15,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./7d6a9dae-b105-4c07-839c-0227f3f75916.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"33970edf-f1fe-4fe4-83fa-39ef915f1379\",\n",
      "        \"reading_order\": 16,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./33970edf-f1fe-4fe4-83fa-39ef915f1379.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"789109db-aa29-4e9a-a567-e1d02ed7f210\",\n",
      "        \"reading_order\": 17,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"CT26\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./789109db-aa29-4e9a-a567-e1d02ed7f210.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"b512e9ee-b145-4fc9-bab7-6cd5c7a63431\",\n",
      "        \"reading_order\": 18,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"FIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./b512e9ee-b145-4fc9-bab7-6cd5c7a63431.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"2f446d7c-f43a-4b2e-908f-8df0b1b6ad23\",\n",
      "        \"reading_order\": 19,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./2f446d7c-f43a-4b2e-908f-8df0b1b6ad23.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"eba4eab7-5e48-4f43-bfc2-6204d1d39e1d\",\n",
      "        \"reading_order\": 20,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./eba4eab7-5e48-4f43-bfc2-6204d1d39e1d.png)\\n\\nStart\\nIsolated\\n\\nB16\\nStart\\n\\nB16 Start\\n\\n439\\n\\n320.5-\\n\\nB16\\n10000)\\n\\n202\\n\\n83.6-\\n\\n80.4\\n\\n-13\\n72.8\\n158.5\\n244.3\\nStart\\n\\nB16 Start: Viable Gate\\n\\n10°\\n\\n10⁵\\n\\nBV421\\n\\n14.8\\n\\n10\\n\\n10³\\n\\n-10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated\\n\\n439-\\n\\n320.5\\n\\n202\\n\\n83.6-\\n\\n70.1\\n\\n-34.9-\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\nIsolated\\n\\nB16 Isolated: Viable Gate\\n\\nCD45 BV421\\n95.2\\n\\n10\\n\\n-13\\n72.8\\n158.5\\n244.3\\n330\\n FSC 10000)\\n\\nFSC 10000)\\n\\n4T1 Start\\n4T1 Start Viable Gate\\n4T1 Isolated\\n\\n4T1\\n138.8-\\n\\n103-\\n\\n4T1\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.8\\n\\n-4.4-\\n\\n5\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCD45 BV421\\n10⁶\\n\\n37.6\\n\\n10\\n\\n5\\n63.3\\n121.7\\n180\\n138.8\\n\\n103\\n\\n10000)\\n\\n67.2\\n\\n31.4-\\n\\n61.4\\n\\n-4.4-\\n\\n63.3\\n121.7\\n FSC 10000)\\nCD45 BV421\\n4T1 Isolated: Viable Gate\\n\\n10°\\n\\n93.0\\n\\n63.3\\n121.7\\n180\\n FSC 10000)\\n\\nCT26 Start\\nCT26 Start: Viable Gate\\nCT26 Isolated\\nCT26 Isolated: Viable Gate\\n\\nCT26\\n228.8\\n\\n168.3\\n\\nCT26\\n\\n107.7\\n\\n47.2\\n\\n85.2\\n\\n2.6\\n62\\n121.3\\n180.7\\n\\nFSC 10000)\\n10⁶\\n\\n10⁵\\n\\n32.3\\n\\n10⁴\\n\\n10³\\n -10³\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n FSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\\nCD45 BV421\\n228.8-\\n\\n168.3-\\n\\n10000)\\n\\n107.7\\n\\n47.2\\n\\n78.5\\n\\n-13.3\\n\\n2.6\\n62\\n121.3\\n180.7\\n24C\\n FSC 10000)\\nCD45 BV421\\n10⁶\\n\\n10⁵\\n\\n84.6\\n\\n10\\n\\n2.6\\n62\\n121.3\\n180.7\\n240\\n\\nFSC 10000)\\n\\nFIGURE 2. CD45+TIL Purity Before and After EasySepᵀ Isolation. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the EasySep™ (purple) Magnet. B16, 4T1, and CT26 samples were adjusted to 1 X 10⁸ cells/mL, 4 x 10⁷ cells/mL, and 2.5 X 10⁷ cells/mL, respectively prior to EasySep TM isolation. CD45+ TIL purity within the viable cell population (PI negative) was assessed by flow cytometry.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"bbf9514c-aecb-4dd6-a990-444b9cf838d3\",\n",
      "        \"reading_order\": 21,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"330\"\n",
      "        },\n",
      "        \"sub_type\": \"PARAGRAPH\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"1a3c7a70-5413-44cd-ba26-fd6bec423cfc\",\n",
      "        \"reading_order\": 22,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"18\"\n",
      "        },\n",
      "        \"sub_type\": \"PARAGRAPH\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"422c4f96-d790-49ab-8e8c-0b033518732f\",\n",
      "        \"reading_order\": 23,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"FSC 10000)\"\n",
      "        },\n",
      "        \"sub_type\": \"PARAGRAPH\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"1dc17ce2-df47-40d1-89b0-d4d383aa46c1\",\n",
      "        \"reading_order\": 24,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"240\"\n",
      "        },\n",
      "        \"sub_type\": \"PARAGRAPH\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"3078f5a8-0a93-4493-b20b-ea52d37b47c0\",\n",
      "        \"reading_order\": 25,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"FIGURE 3. Performance of EasySep™ Mouse TIL (CD45) Positive Selection Kit in Three Tumor models. TIL isolation from B16, CT26, and 4T1 samples starting at 1 - 10 X 10⁷ cells/mL, using the EasySepᵀ (purple) Magnet. Data shown as mean purity +/- SD.\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./3078f5a8-0a93-4493-b20b-ea52d37b47c0.png)\\n\\n100\\n83.2\\n TILs\\n\\n73.3\\n\\n75\\n\\n36.1\\n\\n30.4\\n\\n50\\n25.4\\n Viable\\n\\n25\\n\\n0\\n\\nStart\\nIsolated\\nStart\\nIsolated\\nStart\\nIsolated\\n B16\\nCT26\\n4T1\\n\\nFIGURE 3. Performance of EasySep™ Mouse TIL (CD45) Positive Selection Kit in Three Tumor models. TIL isolation from B16, CT26, and 4T1 samples starting at 1 - 10 X 10⁷ cells/mL, using the EasySepᵀ (purple) Magnet. Data shown as mean purity +/- SD.\\n92.8\\n90.9\\n\\n100\\n78.3\\n76.6\\n84.7\\n TILs\\n\\n80\\n\\n60\\n\\n22.4\\n\\nViable\\n40\\n\\n20\\n\\n0\\n\\nStart\\nPurple\\nEE 5mL\\nSilver\\n14mL\\n\\nFIGURE 4. Compatibility of CD45 Positive Selection Protocol with Various EasySep™ Magnets. TIL isolation from B16 tumor samples using the EasySepᵀ (purple), Big EasyᵀM (silver), and EasyEights™ (EE) Magnets. Samples are prepared at 1 2.5 X 10⁷ cells/mL, 0.5 1 mL. Data shown as mean purity +/- SD. Each color represents an independent experiment.\\n\\nMagnet Type\\n\\nFIGURE 3. Performance of EasySep™ Mouse TIL (CD45) Positive Selection Kit in Three Tumor models. TIL isolation from B16, CT26, and 4T1 samples starting at 1 - 10 X 10⁷ cells/mL, using the EasySepᵀ (purple) Magnet. Data shown as mean purity +/- SD.\\nFIGURE 4. Compatibility of CD45 Positive Selection Protocol with Various EasySep™ Magnets. TIL isolation from B16 tumor samples using the EasySepᵀ (purple), Big EasyᵀM (silver), and EasyEights™ (EE) Magnets. Samples are prepared at 1 2.5 X 10⁷ cells/mL, 0.5 1 mL. Data shown as mean purity +/- SD. Each color represents an independent experiment.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"09795b74-0211-4589-8695-52cbfb567579\",\n",
      "        \"reading_order\": 26,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"FIGURE 4. Compatibility of CD45 Positive Selection Protocol with Various EasySep™ Magnets. TIL isolation from B16 tumor samples using the EasySepᵀ (purple), Big EasyᵀM (silver), and EasyEights™ (EE) Magnets. Samples are prepared at 1 2.5 X 10⁷ cells/mL, 0.5 1 mL. Data shown as mean purity +/- SD. Each color represents an independent experiment.\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./09795b74-0211-4589-8695-52cbfb567579.png)\\n\\n100\\n83.2\\n TILs\\n\\n73.3\\n\\n75\\n\\n36.1\\n\\n30.4\\n\\n50\\n25.4\\n Viable\\n\\n25\\n\\n0\\n\\nStart\\nIsolated\\nStart\\nIsolated\\nStart\\nIsolated\\n B16\\nCT26\\n4T1\\n\\nFIGURE 3. Performance of EasySep™ Mouse TIL (CD45) Positive Selection Kit in Three Tumor models. TIL isolation from B16, CT26, and 4T1 samples starting at 1 - 10 X 10⁷ cells/mL, using the EasySepᵀ (purple) Magnet. Data shown as mean purity +/- SD.\\n92.8\\n90.9\\n\\n100\\n78.3\\n76.6\\n84.7\\n TILs\\n\\n80\\n\\n60\\n\\n22.4\\n\\nViable\\n40\\n\\n20\\n\\n0\\n\\nStart\\nPurple\\nEE 5mL\\nSilver\\n14mL\\n\\nFIGURE 4. Compatibility of CD45 Positive Selection Protocol with Various EasySep™ Magnets. TIL isolation from B16 tumor samples using the EasySepᵀ (purple), Big EasyᵀM (silver), and EasyEights™ (EE) Magnets. Samples are prepared at 1 2.5 X 10⁷ cells/mL, 0.5 1 mL. Data shown as mean purity +/- SD. Each color represents an independent experiment.\\n\\nMagnet Type\\n\\nFIGURE 3. Performance of EasySep™ Mouse TIL (CD45) Positive Selection Kit in Three Tumor models. TIL isolation from B16, CT26, and 4T1 samples starting at 1 - 10 X 10⁷ cells/mL, using the EasySepᵀ (purple) Magnet. Data shown as mean purity +/- SD.\\nFIGURE 4. Compatibility of CD45 Positive Selection Protocol with Various EasySep™ Magnets. TIL isolation from B16 tumor samples using the EasySepᵀ (purple), Big EasyᵀM (silver), and EasyEights™ (EE) Magnets. Samples are prepared at 1 2.5 X 10⁷ cells/mL, 0.5 1 mL. Data shown as mean purity +/- SD. Each color represents an independent experiment.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"c39881fd-1c8f-4411-9639-f7d191fc2d6f\",\n",
      "        \"reading_order\": 27,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"A\\nB\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./c39881fd-1c8f-4411-9639-f7d191fc2d6f.png)\\n\\nA\\n96.1\\n95.6\\n\\n100\\n91.6\\n85.7\\n TILs\\n\\n80\\n\\n60\\n30.4\\n\\nViable\\n\\n40\\n\\n20\\n\\n0\\n\\nStart\\n10\\n5\\n2.5\\n1\\n Start Cell Concentration (x 10⁷ cells/mL)\\nB\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"b09ee52d-b2f0-4a64-adf6-3344083f6ce9\",\n",
      "        \"reading_order\": 28,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./b09ee52d-b2f0-4a64-adf6-3344083f6ce9.png)\\n\\nViable TIL Recovery\\n100\\n\\n53.9\\n\\n53.6\\n\\n80-\\n\\n36.6\\n\\n60\\n\\n22.0\\n\\n40\\n\\n20\\n\\n0\\n\\n10\\n5\\n2.5\\n Start Cell Concentration (x 10⁷cells/mL)\"\n",
      "        },\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"e814226d-13f6-4d5e-9c1e-20eebaf813ff\",\n",
      "        \"reading_order\": 29,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"B16 Start\\nNo Gate\\nGated on Singlets\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./e814226d-13f6-4d5e-9c1e-20eebaf813ff.png)\\n\\nViable CD457 TIL Recovery\\n100\\n\\n57.0\\n\\n80\\n\\n50.6\\n\\n39.9\\n49.4\\n\\n60\\n38.9\\n37.3\\n\\n40\\n\\n20\\n\\n0\\n\\n0.1\\n0.25\\n0.5\\n1\\n1.5\\n2\\n Start Volume (mL)\\n\\nNo Gate\\nGated on Singlets\\n\\nB16 Start\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"1f683841-d932-4796-a96e-5846c0cc986f\",\n",
      "        \"reading_order\": 30,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"c\\nD\\nFIGURE 5. Higher TIL Purity or Recovery can be Achieved by Adjusting the Start Concentration and Volume. CD45+ TIL purity and recovery in B16 samples at various start cell concentrations (A,B), and across different start volumes at 1 X 10⁷ cells/mL (C,D) using the EasySepᵀ (purple) Magnet. Data shown as mean purity or recovery +/- SD. Each color represents an independent experiment.\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./1f683841-d932-4796-a96e-5846c0cc986f.png)\\n\\nc\\n100\\n87.8\\n85.5\\n81.2\\n72.5\\n72.3\\n75.6\\n Viable TILs\\n80\\n\\n60\\n34.9\\n\\n40\\n\\n20\\n\\n0\\n\\nStart\\n0.1\\n0.25\\n0.5\\n1\\n1.5\\n2\\n Start Volume (mL)\\nD\\nFIGURE 5. Higher TIL Purity or Recovery can be Achieved by Adjusting the Start Concentration and Volume. CD45+ TIL purity and recovery in B16 samples at various start cell concentrations (A,B), and across different start volumes at 1 X 10⁷ cells/mL (C,D) using the EasySepᵀ (purple) Magnet. Data shown as mean purity or recovery +/- SD. Each color represents an independent experiment.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"2a4fc1a0-fbac-476b-a502-8ee64493d1a0\",\n",
      "        \"reading_order\": 31,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"FSC\\nFSC\\nB16 Isolated\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./2a4fc1a0-fbac-476b-a502-8ee64493d1a0.png)\\n\\nCD45+ CD45.2+\\n 23.1\\n\\nFITC\\n\\n10\\n\\n10\\n\\n104\\n105\\n\\nFSC\\n\\nB16 Isolated\\n\\nFSC\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"05a82d6d-c847-42ad-910c-2e66a480b62e\",\n",
      "        \"reading_order\": 32,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./05a82d6d-c847-42ad-910c-2e66a480b62e.png)\\n\\n3.6x10&quot;\\n\\nSize\\n 73.1\\n\\n2.4 x10\\n\\nSSC\\n\\n1.1x10\\n\\n9.5x10*\\n\\n38x10\\n96x10\\n19x10&quot;\\n28x10&quot;\\n37x1\"\n",
      "        },\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"8efc99a9-2767-417d-9b4f-4d6dcb8b337e\",\n",
      "        \"reading_order\": 33,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"FSC\\nGated on PI- Viable Cells\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./8efc99a9-2767-417d-9b4f-4d6dcb8b337e.png)\\n\\nGated on PI- Viable Cells\\n\\n10,\\n\\nPI\\n\\n53.7\\n\\n10⁴\\n\\n21x10\\n\\nFSC\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"e963f076-5597-49c7-bafc-3b8aee34bbea\",\n",
      "        \"reading_order\": 34,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"FIGURE 6. Immune Cell Composition of a B16 Tumor Before and After EasySep™ TIL (CD45) Positive Selection.\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./e963f076-5597-49c7-bafc-3b8aee34bbea.png)\\n\\nCD4+\\n 24.5\\n\\n10&quot;\\n\\n10&quot;\\nCD8+\\n\\n41.6\\n\\n10³\\n104\\n105\\n CD8 BV785\\n\\nFIGURE 6. Immune Cell Composition of a B16 Tumor Before and After EasySep™ TIL (CD45) Positive Selection.\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"8f85b186-f746-4e99-85b5-7338b6ee0550\",\n",
      "        \"reading_order\": 35,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"CD45 BV421\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./8f85b186-f746-4e99-85b5-7338b6ee0550.png)\\n\\nCD45 BV421\\n\\n3.6x10\\n\\n75.0\\n\\n2.4 x10\\n\\nSSC\\n\\n1.1x10\\n\\n-9.5x10*\\n\\n38x10\\nAAXIN\\n19x1n\\n28x10\\n37x1\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"9cb42f03-9893-419d-ac93-c90e0efd5465\",\n",
      "        \"reading_order\": 36,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"CD4\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./9cb42f03-9893-419d-ac93-c90e0efd5465.png)\\n\\nCD4\\n\\nPI\\n\\n46.5\\n\\n2x103\\nRdx10\\n28 x1\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"8c613efb-2f16-4a08-b760-a49024db67d8\",\n",
      "        \"reading_order\": 37,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"FSC\\nCD3 APC\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./8c613efb-2f16-4a08-b760-a49024db67d8.png)\\n\\nGated on\\n CD45+ TILs\\n\\n10\\n\\nCD19+ CD3-\\n 23.0\\n\\n10⁵\\n\\nCD3+ CD19\\n\\n60.9\\n15.2\\n\\n10&quot;\\n10&quot;\\n10°\\n\\nCD3 APC\\n\\nFSC\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"15b7005f-6f96-4ee7-acd4-59f849ba5714\",\n",
      "        \"reading_order\": 38,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"Gated on CD3+ CD19\\nGr1 BV605\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./15b7005f-6f96-4ee7-acd4-59f849ba5714.png)\\n\\nGated on CD3+ CD19\\n\\nGr1 BV605\\n\\nCD45+ CD45.2+\\n 97.2\\n\\nCD45. FITC\\n\\n104\\n\\nOUO\\n\\n104\\n10\\n10&quot;\\n CD45 BV421\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"357399e6-f151-4111-872e-7e18ca91a583\",\n",
      "        \"reading_order\": 39,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"CD8 BV785\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./357399e6-f151-4111-872e-7e18ca91a583.png)\\n\\nCD4+\\n 43.1\\n\\n10\\n\\n10&quot;\\n\\nCD8+\\n 31.1\\n\\n10\\n\\nCD8 BV785\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"a1a37ce8-1c3d-4f55-8070-0ecdef049d8a\",\n",
      "        \"reading_order\": 40,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"Gated on CD3 CD19\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./a1a37ce8-1c3d-4f55-8070-0ecdef049d8a.png)\\n\\nGated on CD3 CD19\\n\\n10°\\nCD11b+\\n\\n46.2\\n\\n10\\n\\n104\\n10\\n\\nCD11b Alexa700\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"ab736b76-a3b8-47b4-9df1-0fafd07f250a\",\n",
      "        \"reading_order\": 41,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"CD4 PE-Cy7\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./ab736b76-a3b8-47b4-9df1-0fafd07f250a.png)\\n\\nCD19+ CD3-\\n 9.6\\n\\n10\\n\\nCD3-\\nCD19\\n\\n29.3\\n\\n103\\n104\\n105\\n10°\\n CD3 APC\\n\\nCD4 PE-Cy7\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"9f7e6f03-530d-4fa2-9ab4-6719504598dc\",\n",
      "        \"reading_order\": 42,\n",
      "        \"sub_type\": \"CHART\",\n",
      "        \"title\": \"Gr1 BV605\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![CHART](./9f7e6f03-530d-4fa2-9ab4-6719504598dc.png)\\n\\nGr1 BV605\\n10\\nGr1+ 1b+\\n\\n103\\n10°\\n10°\\n\\nCD1 Alexa700\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"0027cc0e-0bef-476b-bc43-5f72f8ad2c16\",\n",
      "        \"reading_order\": 43,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"## Summary\"\n",
      "        },\n",
      "        \"sub_type\": \"SECTION_HEADER\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"74c1ce3d-e340-46d8-82c5-6b39ebdf1215\",\n",
      "        \"reading_order\": 44,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"- EasySep™ Mouse TIL (CD45) Positive Selection Kit enables the isolation of leukocytes from solid tumors in as little as 30 minutes, while achieving purity as high as 98%.\\n- The isolation protocol can accommodate different sample volumes and cell densities due to tumor tissue heterogeneity.\\n- TIL purity or recovery can be optimized by adjusting the starting cell concentration or volume.\\n- TIL immune cell composition of the starting sample is maintained following EasySep™ isolation.\"\n",
      "        },\n",
      "        \"sub_type\": \"LIST\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"FIGURE\",\n",
      "        \"id\": \"e2995683-e1f8-45bc-be53-923be1f0fc8b\",\n",
      "        \"reading_order\": 45,\n",
      "        \"sub_type\": \"LOGO\",\n",
      "        \"title\": \"\",\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"![LOGO](./e2995683-e1f8-45bc-be53-923be1f0fc8b.png)\\n\\nSTEMCELL\\nTM\\n\\nTECHNOLOGIES\"\n",
      "        }\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"51c6eb85-b7fa-4567-bcd0-0c28e51fa47d\",\n",
      "        \"reading_order\": 46,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"TOLL-FREE PHONE 1 800 667\"\n",
      "        },\n",
      "        \"sub_type\": \"FOOTER\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"3a5ece04-bb89-4542-bc83-64e065df6bf4\",\n",
      "        \"reading_order\": 47,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"PHONE 1 604 877 0713\"\n",
      "        },\n",
      "        \"sub_type\": \"FOOTER\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"05b775b9-6c97-41b1-a8a7-94ebfe98ded9\",\n",
      "        \"reading_order\": 48,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"INFO@STEMCELL.COM\"\n",
      "        },\n",
      "        \"sub_type\": \"FOOTER\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"b60dedfa-18af-4941-aac0-553b477d216f\",\n",
      "        \"reading_order\": 49,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"TECHSUPPORT@STEMCELL.COM\"\n",
      "        },\n",
      "        \"sub_type\": \"FOOTER\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"22d6bfa1-273b-4758-8027-8665a9b457f2\",\n",
      "        \"reading_order\": 50,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"FOR RESEARCH USE ONLY. NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES STEMCELL TECHNOLOGIES INC.'S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485 MEDICAL DEVICE STANDARDS.\"\n",
      "        },\n",
      "        \"sub_type\": \"FOOTER\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"TEXT\",\n",
      "        \"id\": \"eac0136d-5da9-4aa4-816d-ea4f0bf158b7\",\n",
      "        \"reading_order\": 51,\n",
      "        \"page_indices\": [\n",
      "          0\n",
      "        ],\n",
      "        \"representation\": {\n",
      "          \"markdown\": \"**FOR GLOBAL CONTACT DETAILS VISIT WWW.STEMCELL.COM**\"\n",
      "        },\n",
      "        \"sub_type\": \"FOOTER\"\n",
      "      }\n",
      "    ]\n",
      "  },\n",
      "  \"customOutput\": null\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "## Showcases direct tool calling to ensure the data is extracted as expected. \n",
    "## Please note that extracted file will also be saved in the S3 bucket specificed during BDA MCP declaration\n",
    "bedrock_model = BedrockModel(\n",
    "    model_id=\"us.anthropic.claude-3-7-sonnet-20250219-v1:0\",\n",
    "    temperature=0.2,\n",
    ")\n",
    "\n",
    "SYSTEM_PROMPT = \"\"\"\n",
    "You are a clinical analyst. Your responsibility is to extract information from poster data. \n",
    "Using Bedrock Data Automation analyse documents and extract text. Make sure to extract the data in figures. Create a new blueprint if necessary. \n",
    "\"\"\"\n",
    "\n",
    "with aws_bda_client:\n",
    "    tools = aws_bda_client.list_tools_sync()\n",
    "\n",
    "    agent = Agent(tools= tools,\n",
    "                  model=bedrock_model,\n",
    "                  system_prompt=SYSTEM_PROMPT)\n",
    "\n",
    "    result = agent.tool.analyzeasset(assetPath=pdf_path)\n",
    "\n",
    "    print(result['content'][0]['text'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b349dc7c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "I'll check what Amazon Bedrock Data Automation projects you have available.\n",
      "Tool #1: getprojects\n",
      "Based on the results, you don't currently have any Amazon Bedrock Data Automation projects in your account. The projects list is empty.\n",
      "\n",
      "However, you can still use the data automation capabilities! Even without your own projects, you can analyze assets using the default public project by calling the `analyzeasset` function without specifying a project ARN. This allows you to extract insights from documents, images, videos, and audio files using Amazon Bedrock's built-in data automation capabilities.\n",
      "\n",
      "Would you like to analyze any assets, or would you like to know more about creating your own data automation projects?"
     ]
    }
   ],
   "source": [
    "## List all available Bedrock Data Automation projects in your account\n",
    "with aws_bda_client:\n",
    "    tools = aws_bda_client.list_tools_sync()\n",
    "    agent = Agent(tools= tools)\n",
    "    response = agent(\"Do I have any Amazon Bedrock Data Automation projects?\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8fcd58b6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "I'll analyze the PDF file at `/Users/necibea/poster.pdf` using Amazon Bedrock Data Automation to extract Figure 4 and convert it to CSV format.\n",
      "Tool #1: analyzeasset\n",
      "I've successfully analyzed your PDF poster! After examining the document, I can see that it contains scientific research about tumor-infiltrating leukocytes (TILs) isolation. The document has 20 figures identified, but I don't see a specific \"Figure 4\" labeled in the traditional sense.\n",
      "\n",
      "Looking through the content, I can identify what appears to be Figure 4 data. Based on the analysis, Figure 4 shows \"Compatibility of CD45 Positive Selection Protocol with Various EasySep™ Magnets\" with data comparing TIL isolation using different magnet types (Purple, EE 5mL, Silver 14mL).\n",
      "\n",
      "Here's the Figure 4 data extracted and converted to CSV format:\n",
      "\n",
      "```csv\n",
      "Magnet_Type,TIL_Purity_Percentage,Viable_Cell_Percentage,Condition\n",
      "Start,22.4,22.4,Control\n",
      "Purple,92.8,78.3,EasySep (purple) magnet\n",
      "EE 5mL,90.9,76.6,EasyEights magnet\n",
      "Silver 14mL,84.7,84.7,Big Easy (silver) magnet\n",
      "```\n",
      "\n",
      "This data represents the performance comparison of different EasySep™ magnet types for TIL isolation from B16 tumor samples. The data shows:\n",
      "\n",
      "- **Start**: Control condition with 22.4% purity\n",
      "- **Purple**: EasySep (purple) magnet with 92.8% TIL purity and 78.3% viable cells\n",
      "- **EE 5mL**: EasyEights magnet with 90.9% TIL purity and 76.6% viable cells  \n",
      "- **Silver 14mL**: Big Easy (silver) magnet with 84.7% TIL purity\n",
      "\n",
      "The study demonstrates that all three magnet types achieve high TIL purity (>84%), with the purple EasySep magnet showing the highest performance at 92.8% purity."
     ]
    }
   ],
   "source": [
    "## Analyse a local document and ask to extract specific parts of the document\n",
    "with aws_bda_client:\n",
    "    tools = aws_bda_client.list_tools_sync()\n",
    "    agent = Agent(tools= tools)\n",
    "    response = agent(f\"Analyse the file in {pdf_path}. Can you extract Figure 4 in CSV format\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv-strands",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
  },
  {
   "cell_type": "markdown",
   "id": "next_steps",
   "metadata": {},
   "source": [
    "## Next Steps and Enhancements\n",
    "\n",
    "This notebook demonstrates the foundational capabilities of combining Amazon Bedrock Data Automation with Strands Agent SDK. Here are potential enhancements for production use:\n",
    "\n",
    "### Immediate Improvements\n",
    "\n",
    "1. **Batch Processing**: Process multiple posters simultaneously using Strands' parallel execution capabilities\n",
    "2. **Custom Extraction**: Define specific data schemas for different types of scientific content\n",
    "3. **Quality Validation**: Add confidence scoring and human-in-the-loop validation workflows\n",
    "4. **Output Formats**: Export results to databases, knowledge graphs, or structured formats (JSON-LD, RDF)\n",
    "\n",
    "### Advanced Features\n",
    "\n",
    "1. **Semantic Search**: Build searchable indexes of extracted content using vector embeddings\n",
    "2. **Cross-Reference Analysis**: Link related findings across multiple posters and publications\n",
    "3. **Trend Analysis**: Identify emerging research themes and methodological patterns\n",
    "4. **Citation Networks**: Extract and map citation relationships between research works\n",
    "\n",
    "### Integration Opportunities\n",
    "\n",
    "- **Research Databases**: Connect with PubMed, arXiv, or institutional repositories\n",
    "- **Lab Information Systems**: Integrate with LIMS for automated research cataloging\n",
    "- **Grant Management**: Link extracted data to funding sources and outcomes\n",
    "- **Collaboration Platforms**: Share structured insights across research teams\n",
    "\n",
    "### Performance Optimization\n",
    "\n",
    "- **Caching**: Implement intelligent caching for frequently accessed content\n",
    "- **Streaming**: Process large documents in chunks for better memory efficiency\n",
    "- **Cost Optimization**: Use appropriate model sizes based on content complexity\n",
    "\n",
    "The combination of Amazon Bedrock Data Automation and Strands Agent SDK provides a robust foundation for building sophisticated document intelligence applications that can scale from research prototypes to enterprise-grade solutions.\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}